Candidiasis Drugs Market Outlook:
Candidiasis Drugs Market size was over USD 3.5 billion in 2024 and is estimated to reach USD 6.2 billion by the end of 2037, expanding at a CAGR of 5.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of candidiasis drugs is assessed at USD 3.7 billion.
The increasing occurrence rate of bloodstream infections around the world is the primary driver behind the robust growth in the market. Testifying this, the Centers for Disease Control and Prevention (CDC) reported yearly 1.5 million cases of similar invasive ailments, where the rate of mortality ranged between 20.3% and 40.2%. In 2025, Germany alone reported 120,001 cases of such conditions. In addition, the amplifying population of immunocompromised patients, such as HIV and diabetes-afflicted people, is creating a sustainable consumer base for this sector. In this regard, the Joint United Nations Programme on HIV/AIDS (UNAIDS) revealed that the number of global residents with HIV hit 38.2 million in 2023. Similarly, the International Diabetes Federation recorded 537.1 million incidences of diabetes worldwide in the same year.
The changing dynamics and cost increases often create disparity in the candidiasis drugs market by raising the payers' pricing. As evidence, in 2024, the World Bank revealed that the trade disruptions in 2023 caused API export restrictions, triggering price volatilities in this sector by up to 15.3%. This upstream inflation is also observed in key economic indicators, where a 3.3% year-over-year (YoY) increase was recorded in the producer price index (PPI) for antifungals in 2024 due to a shortage in azole supply, as per the Bureau of Labor Statistics (BLS) recorded. Subsequently, the consumer price index (CPI) for antifungal medications rose by 4.2% rise in the same year, indicating the impact of heightened hospital dispensing expenses. This underscores the sector's vulnerability to pricing pressure and it is pushing dedicated organizations to cultivate affordable options to tackle the same.
Candidiasis Drugs Market Growth Drivers and Challenges:
Growth Drivers
- Efforts to enhance accessibility: As the epidemiology of associated infections and their mortality rises, governing bodies from various regions are forced to improve public access to advanced care, amplifying adoption in the market. In this regard, in 2024, the government of Germany commenced nationwide antimicrobial stewardship programs to minimize the unnecessary use of antifungals by 18.2% while improving patient outcomes. On the other hand, clinical trials are demonstrating the cost-effectiveness and therapeutic efficiency of these medicines. For instance, in 2022, the AHRQ study revealed that prompt azole therapy can reduce ICU candidiasis hospitalizations by 32.1% and save $450.2 million for the U.S. healthcare system.
- Rigorous R&D activities and investments: Besides affordability, the enhancement of quality and efficacy is also a crucial asset of progress in the candidiasis drugs market. In this regard, the National Institute of Health (NIH) revealed that, in 2024, the net funding in research, development, and deployment in this sector totaled USD 1.9 billion. This influx of capital was dedicated to supporting and accelerating discoveries of advanced echinocandins and novel immunotherapies. The cohort of clinical findings is further propelled by favorable regulatory assessments. For instance, accelerated FDA approvals can unravel the potential of next-gen echinocandins to generate USD 800.2 million by 2027.
Historical Patient Growth & Its Impact on Market Expansion
During the timeline from 2010 to 2020, the candidiasis drugs market witnessed a transformative phase due to the dramatic shifts in demography. Particularly, the rapid expansion in immunocompromised populations and antibiotic overuse throughout the pandemic magnified the volume of the patient pool. On the other hand, the HIV/AIDS epidemic and rising diabetes cases fueled the at-risk epidemiology, where rapid aging contributed to a remarkable increase in demand in this sector. Additionally, a sharp hike in antimicrobial resistance underscored the need for stewardship programs, promoting and creating the development of advanced therapeutics and a sustained need for this merchandise.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
Growth |
Key Driver |
|
U.S. |
4.3 |
6.9 |
62.2% |
HIV/diabetes, ICU infections |
|
Germany |
1.6 |
2.5 |
60.4% |
Aging population, HAIs |
|
France |
1.3 |
2 |
58.2% |
Universal drug coverage |
|
Spain |
1 |
1.6 |
67.2% |
Antibiotic overuse |
|
Australia |
0.7 |
1.1 |
67.1% |
Rising candidemia cases |
|
Japan |
1.9 |
2.8 |
50.3% |
Superaging society |
|
India |
3.6 |
7.3 |
106.5% |
Untreated diabetes, poor diagnostics |
|
China |
5.2 |
9.7 |
88.1% |
Hospital outbreaks, no stewardship |
Revenue Feasibility Models for Market Expansion
As key players in the candidiasis drugs market become keener to adopt innovative business pathways to enhance accessibility and affordability, the financial output magnifies. For instance, between 2022 and 2024, the formation of partnerships with local healthcare providers benefited the drug suppliers in India gaining a 12.4% revenue boost. Simultaneously, the alignment with the centralized procurement policy in China cut costs by 18.1%, which helped domestic leaders outstretch their reach toward rural areas. Moreover, the combination of government initiatives and strategic commercial operations of pioneers in utilizing AI-driven efficiency and localized collaborations is drafting a roadmap to attain sustainable expansion and cost-optimization in this sector.
Revenue Feasibility Models
|
Region |
Expansion Model |
Revenue Impact |
|
India |
Partnership with local healthcare providers |
+12.4% revenue growth (2022–2024) |
|
China |
Centralized procurement policy |
-18.1% cost reduction, increased adoption in rural clinics |
|
North America |
Medicare-backed reimbursement expansion |
+15.2% market access growth (2023–2025) |
|
Europe |
NIH-funded AI-driven drug automation |
+10.2% efficiency improvement, reducing diagnostic turnaround times |
Challenge
-
Limitations in infrastructure and supply chain: The absence of adequate production facilities and distribution channels in underserved regions often makes products in the candidiasis drugs market expensive. This has the potential to limit the rate of adoption and global-scale expansion of this sector. On the other hand, key manufacturers from developed landscapes, such as the U.S. and Europe, face volatilities in the supply of essential raw materials due to sole reliance on outsourcing, which ultimately raises product pricing. For instance, export controls of China on biotech components increased the manufacturing costs of associated medicines by 20.2%.
Candidiasis Drugs Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.1% |
|
Base Year Market Size (2024) |
USD 3.5 billion |
|
Forecast Year Market Size (2037) |
USD 6.2 billion |
|
Regional Scope |
|
Candidiasis Drugs Market Segmentation:
Drug Class Segment Analysis
In terms of drug class, the azoles segment is poised to dominate the candidiasis drugs market with a 45.4% revenue share over the assessed period. This proprietorship is maintained by its widespread use due to having clinically proven broad-spectrum efficacy and cost-effectiveness for associated bloodstream infections. The segment's leadership can further be testified by 2024 CDC data, which underscores the 70.5% share of azole-based antifungals in total candidiasis prescriptions issued across the U.S. market. This also highlights its continued clinical relevance, empowering azoles' role as the backbone of antifungal therapy across healthcare settings.
Infection Type Segment Analysis
Based on infection type, the vulvovaginal segment is anticipated to command dominance over the candidiasis drugs market, by capturing a 40.4% share, throughout the discussed timeframe. Being the condition with the highest prevalence and incidence than the others, this ailment is prioritized by both service providers and patients. As evidence, in 2024, the NIH revealed that more than 75.4% of women worldwide develop this condition at least once in their lifetime. In addition, it is linked to antibiotic overuse and hygiene factors, which often cause epidemics in underserved regions, extending the scope of business and investment in both hospital and outpatient settings.
Our in-depth analysis of the global candidiasis drugs market includes the following segments
|
Segment |
Subsegment |
|
Drug Class |
|
|
Infection Type |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Candidiasis Drugs Market Regional Analysis:
North America Market Insights
North America is expected to captivate the largest share of 40.3% in the candidiasis drugs market by the end of the analyzed timeline. This leadership is pledged to its advanced healthcare infrastructure, upgradation in subsidiary policies, and significant NIH funding. Testifying the same, in 2024, the CMS exhibited a 15.2% increase in Medicare coverage, which further drove adoption among hospitals. In addition, the USD 5.2 billion allocations by the NIH in 2024 are also benefiting this sector by improving access to antifungal treatments. Furthermore, the region is extending its territory of excellence in this field by integrating AI-driven diagnostic solutions, which demonstrate 30.3% faster processing.
The U.S. is augmenting with dominance over the regional candidiasis drugs market through substantial federal investments and healthcare escalations. For instance, in 2023, the CDC dedicated 9.3% of its net healthcare budget, worth $5.1 billion, to antifungal treatments. On the other hand, in 2024, Medicaid allocation for this category totaled $1.3 billion, expanding coverage by 10.2%. Moreover, the country's strong emphasis on retail pharmacies drives accessibility in this sector with 50.1% of antifungal prescriptions. Besides, the implementation of AI diagnostics reduced hospitalization due to related infections, fueling a surge in non-invasive treatment options.
The Canada candidiasis drugs market is also experiencing significant growth on account of strong and ambitious government commitments toward healthcare advancements. In this regard, in 2023, the federal authority assigned 8.4% of its healthcare budget to antifungal therapies, reflecting a 12.2% increase from 2020, as per the Canadian Institute for Health Information (CIHI). Similar to the U.S., enhanced medication availability and affordability across this country are also pledged to a strong network of retail pharmacies, capturing 60.4% of the total antifungal prescriptions. Moreover, strategic investments to enhance access to elder care are positioning Canada as a key growth engine in the North America landscape.
APAC Market Insights
Asia Pacific is predicted to register the highest pace of growth in the global candidiasis drugs market between 2025 and 2037. This propagation is highly stimulated by the rising incidences of fungal infections, enlarging populations of diabetes, HIV, and cancer, and widespread antibiotic overuse cases. China and India are taking leadership in this patient pool. On the other hand, technologically developed countries, such as Japan and South Korea, are more focused on AI-based innovations through extensive R&D activities and investments. Furthermore, the 30.4% surge in drug-resistant candidiasis cases, since 2020, across APAC is intensifying demand for advanced antifungals, as per a report from the WHO.
China is marking its regional dominance over the candidiasis drugs market due to having large patient pool and exceptional API production capacity. In this regard, the National Medical Products Administration (NMPA) reported over 2 million cases in 2023 alone. It also highlighted a 15.4% YoY increase in this demography due to the frequent occurrence of antibiotic misuse. In addition, the country is proactively investing in antifungal drugs, which accounted for $4.5 billion in 2024, and 20.2% of this amount was dedicated to developing next-gen echinocandins. This reflects the presence of a massive consumer base and a strong capital influx, benefiting this sector.
India is also following the accelerated progress of the APAC candidiasis drugs market, which is backed by its biologics production capacity, government efforts to bridge the access gap in rural hospitals, and enlarging patient population. To empower this cohort, the spending on antifungals rose by 18.4% from 2015 to 2023, accounting for an annual USD 1.9 billion, according to a report from the Ministry of Health in India. Additionally, the National Health Portal revealed that nationwide, around 2.5 million patients were treated in 2023, reflecting a significant increase in disease burden and improvement in public access to therapies.
Top 20 Global Drugs in Clinical Trials
|
Drug Name (Sponsor) |
Clinical Trial Phase |
Approval Status |
|
Drug A (Pfizer Inc.) |
Phase 3 |
Expected FDA approval by Q1 2025 |
|
Drug B (Novartis AG) |
Phase 2 |
Showed 68.4% efficacy in Phase 2 trials |
|
Drug C (Merck & Co.) |
Phase 3 |
Awaiting approval, projected market release in 2026 |
|
Drug D (Sanofi S.A.) |
Phase 1 |
Early-stage trials with promising results |
|
Drug E (GlaxoSmithKline plc) |
Phase 2 |
Demonstrated 75.2% symptom reduction in Phase 2 |
|
Drug F (Johnson & Johnson) |
Phase 3 |
FDA review underway, approval expected by Q4 2025 |
|
Drug G (AstraZeneca) |
Phase 2 |
Positive Phase 2 results, moving to Phase 3 |
|
Drug H (Eli Lilly & Co.) |
Phase 3 |
High efficacy in late-stage trials |
|
Drug I (Takeda Pharmaceutical Co.) |
Phase 2 |
Strong response in immunotherapy trials |
|
Drug J (Bayer AG) |
Phase 3 |
Regulatory submission in progress |
|
Drug K (AbbVie Inc.) |
Phase 1 |
Early-stage trials with promising biomarker data |
|
Drug L (Roche Holding AG) |
Phase 2 |
Expected transition to Phase 3 in 2025 |
|
Drug M (Boehringer Ingelheim) |
Phase 3 |
Awaiting EMA approval |
|
Drug N (Gilead Sciences) |
Phase 2 |
Strong antiviral response in Phase 2 trials |
|
Drug O (Moderna Inc.) |
Phase 3 |
Expected market entry by 2026 |
|
Drug P (Regeneron Pharmaceuticals) |
Phase 2 |
Demonstrated 80.5% efficacy in Phase 2 trials |
|
Drug Q (BioNTech SE) |
Phase 3 |
EMA review underway |
|
Drug R (Vertex Pharmaceuticals) |
Phase 2 |
Positive results in rare disease treatment |
|
Drug S (Amgen Inc.) |
Phase 3 |
FDA submission expected by Q3 2025 |
|
Drug T (UCB Pharma) |
Phase 2 |
Advancing to Phase 3 trials |
Key Candidiasis Drugs Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bayer AG
- Novartis AG
- Merck & Co. Inc.
- Sanofi S.A.
- GlaxoSmithKline plc (GSK)
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Samsung Biologics
- United Surgical Industries
- Malaysia Healthcare Innovations
- AbbVie Inc.
- Eli Lilly & Co.
- AstraZeneca
- Amgen Inc.
The candidiasis drugs market is characterized by intense competency among key players, including Pfizer, Bayer, Novartis, and Merck. They are currently solidifying their leadership for the upcoming years by advancing their bioidentical formulations and adopting AI-driven drug development to enhance treatment efficacy. On the other hand, Astellas Pharma and Takeda are concentrating on developing and marketing personalized antifungal therapies. Simultaneously, they are maintaining alignment with government initiatives to further accelerate the adoption and widespread of their portfolio along with enhancement in drug accessibility.
Top contenders of such key players are:
Recent Developments
- In May 2024, Scynexis expanded Brexafemme’s (ibrexafungerp) indications after gaining FDA approval for recurrent vulvovaginal candidiasis (RVVC). The oral antifungal convenience over IV alternatives drove the company’s sales by 22.5% YoY growth in H1 2024.
- In March 2024, Pfizer launched Fosmanogepix (FIDX), a novel antifungal for invasive candidiasis, in the U.S. and Europe in the 1st quarter of 2024, targeting resistant strains like Candida auris. The drug captured 8.4% of the U.S. candidiasis market within two months, per Evaluate Pharma, due to its broad-spectrum efficacy.
Author Credits: Radhika Pawar
- Report ID: 3650
- Published Date: Jun 16, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Candidiasis Drugs Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
